Vigil Neuroscience, Inc. (VIGL)
NASDAQ: VIGL · Real-Time Price · USD
1.790
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Vigil Neuroscience Employees
Vigil Neuroscience had 69 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
69
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,221,101
Market Cap
83.54M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69 | 0 | - |
| Dec 31, 2023 | 69 | 13 | 23.21% |
| Dec 31, 2022 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VIGL News
- 26 days ago - Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference - GlobeNewsWire
- 6 weeks ago - Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates - GlobeNewsWire
- 6 weeks ago - Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewsWire
- 3 months ago - Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 3 months ago - Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - Benzinga
- 3 months ago - Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - GlobeNewsWire
- 7 months ago - Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - GlobeNewsWire